Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SLC8B1 | Q6J4K2 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.43 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31071906 | 1.00 | TP53 (1.00) | TP53MAPTRECQLCYP1A2CYP2C9 | |
| SCHEMBL10044117 | 0.88 | TP53 (0.79) | TP53MAPTRECQLCYP1A2CYP2C9 | |
| SCHEMBL10929981 | 0.87 | MAPT (0.77) | TP53MAPTRECQLCYP1A2CYP2C9 | |
| SCHEMBL7196864 | 0.76 | MAPT (0.61) | TP53MAPTRECQLCYP1A2CYP2C9 | |
| SCHEMBL10926019 | 0.75 | MAPT (0.60) | TP53MAPTRECQLCYP1A2CYP2C9 | |
| SCHEMBL8117192 | 0.75 | MAPT (0.60) | TP53MAPTRECQLCYP1A2CYP2C9 | |
| SCHEMBL28355878 | 0.72 | MAPT (0.56) | TP53MAPTRECQLCYP1A2CYP2C9 | |
| SCHEMBL10929004 | 0.72 | MAPT (0.56) | TP53MAPTRECQLCYP1A2CYP2C9 | |
| SCHEMBL5435436 | 0.72 | MAPT (0.56) | TP53MAPTRECQLCYP1A2CYP2C9 | |
| SCHEMBL4371172 | 0.71 | TP53 (0.55) | TP53MAPTRECQLCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119564606-A | Micelle mixed system for enhancing effect of irreversible electroporation on pancreatic cancer treatment and preparation method thereof | 华中科技大学同济医学院附属协和医院 | 2025-03-07 | — | — | CN | claimed |
| CN-118787751-A | Use of LSD1 inhibitors in combination with drugs for the treatment of cancer | 中国科学院上海药物研究所 | 2024-10-18 | — | — | CN | claimed |
| WO-2024213057-A1 | USE OF COMBINATION OF LSD1 INHIBITOR AND DRUG TO TREAT CANCER | 中国科学院上海药物研究所 | 2024-10-17 | — | — | WO | claimed |
| EP-3549580-B1 | ENDOPLASMIC RETICULUM-TARGETING NANOVEHICLES | UNIV NAT CHENG KUNG (TW) | 2024-06-26 | — | — | EP | claimed |
| CN-115697420-A | Method and medicine for treating herler's syndrome | 北京辑因医疗科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-113528582-B | Method and medicine for targeted editing of RNA based on LEAPER technology | 博雅辑因（北京）生物科技有限公司 | 2022-05-17 | — | — | CN | claimed |
| US-12584149-B2 | Nuclease-mediated genome editing of primary cells and related kits | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| CN-121698982-A | Isolated polypeptide for inducing mitochondrial calcium overload and application thereof | 华南理工大学 | 2026-03-20 | — | — | CN | disclosed |
| US-20260069638-A1 | GENE EDITING FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA | UNIV MADRID CARLOS III (ES) | 2026-03-12 | — | — | US | disclosed |
| US-12508249-B2 | Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis | Cartesian Therapeutics Inc. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4667492-A2 | TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES | Ramot at Tel-Aviv University Ltd. (IL) | 2025-12-24 | — | — | EP | disclosed |
| EP-4659754-A1 | USE OF LITHIUM-CONTAINING COMPOUNDS IN TREATMENT OF TUMORS | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2025-12-10 | — | — | EP | disclosed |
| US-12472167-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity | CARTESIAN THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20090281077-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | HINTERMANN SAMUEL | 2009-11-12 | — | — | US | disclosed |
| US-20060004062-A1 | Compounds for inhibiting insulin secretion and methods related thereto | MITOKOR (US) | 2006-01-05 | — | — | US | disclosed |
| US-6958352-B2 | Compounds for inhibiting insulin secretion and methods related thereto | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-25 | — | — | US | disclosed |
| US-20040044049-A1 | Compounds for inhibiting insulin secretion and methods related thereto | MITOKOR | 2004-03-04 | — | — | US | disclosed |
| EP-1322314-A2 | TREATMENT OF DIABETES MELLITUS BY INHIBITION OF MITOCHONDRIAL CALCIUM/SODIUM ANTIPORTER | MITOKOR (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020082193-A1 | Inhibition of mitochondrial calcium/sodium antiporter | MITOKOR | 2002-06-27 | — | — | US | disclosed |
| WO-2002024204-A2 | TREATMENT OF DIABETES MELLITUS BY INHIBITION OF MITOCHONDRIAL CALCIUM/SODIUM ANTIPORTER | MITOKOR (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281077-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, CS | TP53 3237/4885MAPT 1856/4885RECQL 1605/4885 |
| US-20020082193-A1 | Inhibition of mitochondrial calcium/sodium antiporter | MCU, SLC8B1, SLC25A20 | TP53 2205/4885MAPT 2521/4885RECQL 2054/4885 |
| US-20060004062-A1 | Compounds for inhibiting insulin secretion and methods related thereto | IAPP, GPR119, INSR | TP53 3278/4885MAPT 3794/4885RECQL 1726/4885 |
| US-20040044049-A1 | Compounds for inhibiting insulin secretion and methods related thereto | IAPP, GPR119, IRS1 | TP53 4184/4885MAPT 3914/4885RECQL 2066/4885 |
| US-12508249-B2 | Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis | HLA-C, CPA3, HLA-A | TP53 1077/4885MAPT 2948/4885RECQL 4408/4885 |
| US-12584149-B2 | Nuclease-mediated genome editing of primary cells and related kits | ADAR, RNASE1, CPSF6 | TP53 386/4885MAPT 4302/4885RECQL 547/4885 |
| US-20260069638-A1 | GENE EDITING FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA | COL14A1, COL2A1, DDR1 | TP53 1532/4885MAPT 3621/4885RECQL 98/4885 |
| US-12472167-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity | CD74, CCR1, MSR1 | TP53 504/4885MAPT 2251/4885RECQL 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.